Evidence map›Paper›PMID 40305997›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2025

Genomic crosstalk between carbachol, a muscarinic receptor agonist, and the long-acting β

Varuna Jayasinghe, Radhika Joshi, Taruna Joshi, Tamkeen U Paracha, Cora Kooi, Mahmoud M Mostafa, Carla M T Bauer, Steven J Charlton, Oleg Iartchouk, Ashley Maillet and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Varuna JayasingheLung Health Research Group, Department of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Radhika JoshiLung Health Research Group, Department of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Taruna JoshiLung Health Research Group, Department of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Tamkeen U ParachaLung Health Research Group, Department of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Cora KooiLung Health Research Group, Department of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Mahmoud M MostafaLung Health Research Group, Department of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Carla M T BauerNovartis Biomedical Research, Cambridge, Massachusetts.
Steven J CharltonOMass Therapeutics, Oxford, United Kingdom.
Oleg IartchoukNovartis Biomedical Research, Cambridge, Massachusetts.
Ashley MailletNovartis Biomedical Research, Cambridge, Massachusetts.
Melody K MorrisNovartis Biomedical Research, Cambridge, Massachusetts.
Vera M RudaNovartis Biomedical Research, Cambridge, Massachusetts.
David A SandhamNovartis Biomedical Research, Basel, Switzerland.
Yanqun WangNovartis Biomedical Research, Cambridge, Massachusetts.
Robert NewtonLung Health Research Group, Department of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Mark A GiembyczLung Health Research Group, Department of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: giembycz@ucalgary.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many patients with chronic obstructive pulmonary disease are susceptible to recurrent exacerbations. In this study, we hypothesized that endogenous acetylcholine (ACh) may act as a proinflammatory mediator because long-acting muscarinic receptor antagonists protect against exacerbations, which have an inflammatory basis. This possibility was explored by determining if carbachol (CCh), a stable ACh analog, was a genomic stimulus in BEAS-2B bronchial epithelial cells. The ability of CCh to interact with indacaterol (Ind), a long-acting β

Indexed as

Adrenergic beta-2 Receptor AgonistsCarbacholEpithelial CellsIndansMuscarinic AgonistsQuinolonesBronchiCell LineGene Expression RegulationHumansReceptors, Adrenergic, beta-2Adrenergic beta-2 Receptor AgonistsCarbacholindacaterolIndansMuscarinic AgonistsQuinolonesReceptors, Adrenergic, beta-2CarbacholChronic obstructive pulmonary diseaseGene expression changesGenomic Gq-Gs cross talkIndacaterol

Identifiers

PMID40305997
PMCPMC12264567

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.